Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 29, 2015 9:09 PM ET


Company Overview of Capricor Therapeutics, Inc.

Company Overview

Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of novel therapeutics to prevent and treat cardiovascular diseases. Its lead product candidates include CAP-1002 and Cenderitide. The company was founded in 2005 and is based in Beverly Hills, California.

8840 Wilshire Boulevard

2nd Floor

Beverly Hills, CA 90211

United States

Founded in 2005

28 Employees



Key Executives for Capricor Therapeutics, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 52
Total Annual Compensation: $232.9K
Executive Vice President, General Counsel and Secretary
Age: 62
Total Annual Compensation: $243.8K
Vice President of Medical Affairs
Age: 53
Total Annual Compensation: $225.0K
Compensation as of Fiscal Year 2014.

Capricor Therapeutics, Inc. Key Developments

Capricor Therapeutics, Inc. Announces Resignation of Andrew Hamer as Vice President of Medical Affairs, Effective on or About July 30, 2015

On July 2, 2015, Capricor Therapeutics, Inc. accepted the resignation of Andrew Hamer, M.D., Vice President of Medical Affairs. Dr. Hamer's resignation will be effective on or about July 30, 2015.

Capricor Therapeutics Appoints Houman Hemmati as Vice President of Medical and Clinical Development for New Therapies

Capricor Therapeutics, Inc. announced the appointment of Houman Hemmati, M.D., Ph.D. to the newly created position of Vice President of Medical and Clinical Development for New Therapies. In this role, Dr. Hemmati will work to drive promising new therapies such as Capricor's exosome platform into clinical development as he works closely with the R&D, manufacturing and product development teams. Prior to joining Capricor, Dr. Hemmati, an ophthalmologist, was Director of Clinical Development at Allergan, where responsibilities included early to late stage clinical trial development of high profile ophthalmic products such as Restasis-X as well as Allegan's androgen based ophthalmic treatment and AGN 199201 for presbyopia. Prior to his time at Allergan, he co-founded Avicenna Pharmaceuticals in Paris, France, to advance a technology based on cancer stem cell mutations he had discovered at Caltech.

Capricor Therapeutics Announces Receipt of Food and Drug Administration Clearance for the Phase I/II Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy Related Cardiomyopathy

Capricor Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) have cleared its Investigational New Drug Application (IND) for the clinical development of CAP-1002 for the treatment of patients with Duchenne Muscular Dystrophy (DMD) related cardiomyopathy. CAP-1002 is Capricor's allogeneic, cardiosphere-derived cell (CDC) therapy already in clinical development for the treatment of heart disease. The HOPE-DUCHENNE trial is designed to enroll up to 24 patients in a randomized, multi-center study evaluating the safety and preliminary efficiency of CAP-1002. Patients will receive CAP-1002 in all three coronary arteries which will allow for it to be delivered to wide areas of the myocardium similar to that which was used earlier this year in the DYNAMIC trial. Previously, Capricor was granted orphan drug designation by the FDA for CAP-1002 used for the treatment of cardiomyopathy associated with DMD.

Similar Private Companies By Industry

Company Name Region
Biosome, Inc. United States
Tinea Pharmaceuticals, Inc. United States
VisEn Medical, Inc. United States
GrassRoots Biotechnology, Inc. United States
Archivex, LLC United States

Recent Private Companies Transactions

Private Placement
February 3, 2015
Private Placement
January 9, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Capricor Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at